Stock of the Day

April 3, 2023

Petco Health and Wellness (WOOF)

$2.38
+$0.01 (+0.4%)
Market Cap: $768.38M

About Petco Health and Wellness

Petco Health and Wellness Company, Inc., operates as a health and wellness company, focuses on enhancing the lives of pets, pet parents, and its Petco partners in the United States, Mexico, and Puerto Rico. The company provides veterinary care, grooming, training, tele-health, and Vital Care and pet health insurance services, as well as veterinary services through Vetco mobile clinics. It also offers pet consumables, supplies, and services through its petco.com, petcoach.co, petinsurancequotes.com, and pupbox.com websites. The company offers its products under the WholeHearted, Reddy, and Well & Good brands. Petco Health and Wellness Company, Inc. was founded in 1965 and is headquartered in San Diego, California.

Today's Trend

Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) shares have increased as investors respond to a strong fiscal Q2 earnings beat and evidence that the company’s turnaround is improving profitability. However, flat revenue growth and mixed analyst views are limiting enthusiasm.

  • Petco reported fiscal Q2 earnings per share of $0.13, above the $0.07 consensus estimate and up from $0.05 a year earlier. Adjusted earnings were reported at $0.16 by Zacks, also exceeding expectations. Revenue was approximately $1.49 billion, in line with forecasts. Petco Q2 EPS beat
  • Net income rose to $38.7 million, while operating cash flow nearly doubled. Management attributed part of the improvement to stronger consumables and services performance, omnichannel initiatives, and a one-time tariff refund. Petco turnaround gains
  • Petco reaffirmed its flat-to-1.5% full-year sales outlook and forecast fiscal 2026 adjusted EBITDA of $415 million to $430 million, supporting the view that cost controls and operational improvements can drive earnings even without significant sales growth. Petco fiscal 2026 outlook
  • Analyst opinions remain divided. RBC Capital maintained a Buy rating, while Morgan Stanley kept a Hold rating. Robert W. Baird raised its price target to $3.25 but retained a Neutral rating. RBC Buy rating
  • BNP Paribas Exane cut its price target to $2.11 and assigned an Underperform rating. UBS lowered its target to $3.50 and retained a Neutral rating, underscoring concerns about limited revenue momentum and execution risk. Analyst caution after Petco earnings

Recent News